Our Services
Medical Information
Helpful Resources
Published on: 9/14/2026
Cymbalta (duloxetine) is not generally considered a high-risk heart medication, but it can modestly raise blood pressure and heart rate, and those effects carry more weight after age 65 when hypertension, coronary disease, or arrhythmias are already present. Older adults also face added considerations such as dizziness and orthostatic blood pressure drops that increase fall risk, low sodium levels, and interactions with blood thinners, other antidepressants, or blood pressure drugs. Existing cardiac conditions, kidney or liver function, dose changes, and how quickly the drug is started or stopped all influence individual risk, so periodic blood pressure and pulse monitoring is usually recommended. There are several important factors to consider, including warning signs that warrant urgent attention, described below.
If you are noticing chest discomfort, a racing or irregular heartbeat, unusual dizziness, swelling, or blood pressure readings that are higher than your normal range, it helps to sort out whether your medication, your heart, or something else entirely is driving the change before your next appointment. A free, instant, online symptom check can help you organize what you are feeling, flag symptoms that need prompt medical review, and prepare clearer questions for your prescriber so any dose adjustment or monitoring plan happens sooner rather than later.
Last reviewed for medical accuracy: 09/13/2026
Cymbalta is the brand name for duloxetine, a prescription medication in a class called serotonin–norepinephrine reuptake inhibitors (SNRIs). It’s commonly used to treat:
By increasing levels of serotonin and norepinephrine in the brain, Cymbalta helps improve mood and manage pain signals.
While Cymbalta is generally safe for many people, it does carry some effects on blood pressure and heart function:
Blood pressure increases
• Clinical trials have shown small average rises in systolic (1–3 mm Hg) and diastolic (1–2 mm Hg) blood pressure at doses up to 120 mg/day.
• A small percentage of patients develop hypertension (high blood pressure) that may require dose reduction or stopping the medicine.
Heart rate changes
• Some people experience a modest increase in resting heart rate (2–3 beats per minute).
• Rarely, palpitations or feelings of a racing heart have been reported.
Orthostatic hypotension (postural low blood pressure)
• This can cause lightheadedness or dizziness when standing up quickly.
• More common in people taking higher doses or those already on blood-pressure-lowering drugs.
Risk of falls
• Dizziness or drops in blood pressure can increase fall risk, especially in older adults.
Serious cardiovascular events
• Very rarely, reports exist of arrhythmias or myocardial infarction, but direct causation is not well established.
• Cymbalta is not known to significantly prolong the QT interval.
As we get older, our bodies handle medications differently:
In people over 65 taking Cymbalta, you may see:
To minimize any heart or blood-pressure risks with Cymbalta:
Baseline measurements
Start low, go slow
Regular follow-up
Stay hydrated
Stand up slowly
Review other medications
Report any concerns
For many older adults, Cymbalta provides meaningful relief from depression, anxiety or chronic pain that can improve overall quality of life. The key is:
When used thoughtfully, the benefits of mood stabilization and pain reduction often outweigh the small potential impact on blood pressure and heart rate.
Even if you feel the medication is helping, certain warning signs should prompt immediate evaluation:
For non-urgent but concerning symptoms, you might consider a free, online symptom check, using the doctor approved Ubie Symptom Checker. It can help clarify whether you need to seek immediate in-person care.
Cymbalta is not inherently “dangerous” for your heart or blood pressure after age 65, but it does require thoughtful use:
Always weigh the symptom relief you gain against any side effects you experience. If at any time you feel something could be life-threatening or seriously wrong, speak to a doctor right away.
(References)
* Stevens DL. Duloxetine-associated tachycardia. Ann Pharmacother. 2008 Oct;42(10):1511-3. doi: 10.1345/aph.1L108. Epub 2008 Aug 26. PMID: 18728105.
* Kaufman KR, Podolsky D, Greenman D, Madraswala R. Antidepressant-selective gynecomastia. Ann Pharmacother. 2013 Jan;47(1):e6. doi: 10.1345/aph.1R491. Epub 2013 Jan 16. PMID: 23324513.
* Russell JW, Zilliox LA. Diabetic neuropathies. Continuum (Minneap Minn). 2014 Oct;20(5 Peripheral Nervous System Disorders):1226-40. doi: 10.1212/01.CON.0000455884.29545.d2. PMID: 25299279; PMCID: PMC4208099.
* Buoli M, Serati M, Cahn W. Alternative pharmacological strategies for adult ADHD treatment: a systematic review. Expert Rev Neurother. 2016;16(2):131-44. doi: 10.1586/14737175.2016.1135735. Epub 2016 Jan 14. PMID: 26693882.
* Shelton RC. Serotonin and Norepinephrine Reuptake Inhibitors. Handb Exp Pharmacol. 2019;250:145-180. doi: 10.1007/164_2018_164. PMID: 30838456.
* Behlke LM, Lenze EJ, Carney RM. The Cardiovascular Effects of Newer Antidepressants in Older Adults and Those With or At High Risk for Cardiovascular Diseases. CNS Drugs. 2020 Nov;34(11):1133-1147. doi: 10.1007/s40263-020-00763-z. PMID: 33064291; PMCID: PMC7666056.
* Maideen NMP, Rajkapoor B, Muthusamy S, Ramanathan S, Thangadurai SA, Sughir AA. A Review on Pharmacokinetic and Pharmacodynamic Drug Interactions of Adrenergic β-blockers with Clinically Relevant Drugs-An Overview. Curr Drug Metab. 2021;22(9):672-682. doi: 10.2174/1389200222666210614112529. PMID: 34182907.
* Richard MJ, Driban JB, McAlindon TE. Pharmaceutical treatment of osteoarthritis. Osteoarthritis Cartilage. 2023 Apr;31(4):458-466. doi: 10.1016/j.joca.2022.11.005. Epub 2022 Nov 19. PMID: 36414224.
* Bragg S, Marrison ST, Haley S. Diabetic Peripheral Neuropathy: Prevention and Treatment. Am Fam Physician. 2024 Mar;109(3):226-232. PMID: 38574212.
* Pillinger T, Arumuham A, McCutcheon RA, D'Ambrosio E, Basdanis G, Branco M, Carr R, Finelli V, Furukawa TA, Gee S, Heald A, Jauhar S, Ma Z, Mancini V, Moulton C, Salanti G, Taylor DM, Tomlinson A, Young AH, Efthimiou O, Howes OD, Cipriani A. The effects of antidepressants on cardiometabolic and other physiological parameters: a systematic review and network meta-analysis. Lancet. 2025 Nov 1;406(10515):2063-2077. doi: 10.1016/S0140-6736(25)01293-0. Epub 2025 Oct 21. PMID: 41135546.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.